Dogwood Therapeutics Inc. Ordinary Shares DWTX 深 滬
已收盤 12-24 16:00:00 美东时间
4.38
+0.500
+12.89%
華盛通- 最 高4.4094
- 今 開3.96
- 成交量 4.26万股
- 最 低 3.88
- 昨 收 3.88
- 總市值 1004.42万
- 52周最高 29.28
- 市盈率 靜 --
- 換手率 1.86%
- 52周最低 1.87
- 委 比 -71.01%
- 總股本 229.32万
- 歷史最高 417.75
- 量 比 0.36
- 振 幅 13.64%
- 歷史最低 1.87
- 每 手 1
- 風險率 2.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
Dogwood Therapeutics Inc's (NYSE:DWTX) short interest as a percent of float has...
12-25 00:00
Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- The overall study dropout rate of ~4.4% is far below rates typically
12-22 23:17
Dogwood Therapeutics Files For New Intellectual Property Protection For Synthetic Halneuron
Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new intellectual property
12-02 21:04
Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement
On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade
11-29 03:52
Dogwood Therapeutics Enrolls First 100 Patients In Ongoing HALT-CINP Phase 2b CINP Trial
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well toleratedATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood
11-11 21:47
Dogwood Therapeutics Q3 EPS $(8.20) Misses $(1.58) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.20) per share which missed the analyst consensus estimate of $(1.58) by 418 percent. This is a 300 percent decrease over losses of $(2.05) per share
11-06 21:50
Dogwood Therapeutics Announces Business Combination Plans
Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On October 9, 20...
10-10 04:55
Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the
10-07 20:49
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Electric aircraft maker Beta Technologies files for U.S. IPO
Beta Technologies, a U.S. electric-aircraft developer backed by Amazon, has submitted paperwork to go public via a U.S. IPO, seeking to capitalize on the strong equity market environment. The company,...
09-29 22:08
